CLINICAL STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Three-Pronged attack on tough stomach cancers
Disease control OngoingThis small, early-stage study is testing whether combining an immunotherapy drug (pembrolizumab) with chemotherapy and radiation can help control a type of stomach cancer that cannot be removed by surgery. The goal is to see if this three-part approach is safe and can shrink or e…
Matched conditions: CLINICAL STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New combo treatment trial aims to stop stomach Cancer's return
Disease control OngoingThis study is comparing two treatment approaches for patients with a specific type of stomach or gastroesophageal junction cancer that has not spread widely. The goal is to see if using an immunotherapy drug (atezolizumab) combined with chemotherapy before and after surgery works…
Matched conditions: CLINICAL STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug combo aims to boost immune system against stomach and esophageal cancers
Disease control TerminatedThis study is testing whether adding two immunotherapy drugs, nivolumab and ipilimumab, to standard chemotherapy and radiation can better treat certain cancers of the esophagus and stomach junction. It involves patients who are scheduled for surgery. The goal is to see if this co…
Matched conditions: CLINICAL STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New combo attack on stomach cancer before surgery
Disease control OngoingThis study is testing a new treatment approach for patients with stomach or gastroesophageal cancer that can be surgically removed. It combines two immunotherapy drugs (nivolumab and ipilimumab) with chemotherapy and radiation before surgery, aiming to shrink the tumor and help t…
Matched conditions: CLINICAL STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Scientists test new drug duo to fight tough cancers
Disease control OngoingThis early-stage study is testing a new combination of two drugs, sonidegib and pembrolizumab, for people with advanced solid tumors that have spread. The main goals are to find the safest dose of the combination and see if it helps shrink or control the cancer. The study is enro…
Matched conditions: CLINICAL STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
Double-Punch immunotherapy trial aims to wipe out tumors before esophageal cancer surgery
Disease control OngoingThis study is testing whether a powerful combination of treatments can shrink or eliminate tumors before surgery for esophageal and gastroesophageal junction cancers. Patients receive standard chemotherapy and radiation alongside an immunotherapy drug (pembrolizumab), followed by…
Matched conditions: CLINICAL STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Modified virus tested to attack tough esophageal cancers
Disease control OngoingThis early-stage study is testing the safety of adding a specially designed virus (OBP-301) to standard chemotherapy and radiation for patients with advanced esophageal or gastroesophageal cancer who are not candidates for surgery. The virus is meant to infect and kill cancer cel…
Matched conditions: CLINICAL STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
New combo therapy aims to shrink tumors before esophageal cancer surgery
Disease control OngoingThis study is testing whether adding immunotherapy drugs to standard chemotherapy before surgery can better control cancer in the esophagus or where the stomach meets the esophagus. The goal is to shrink the tumor as much as possible before an operation to remove it. Researchers …
Matched conditions: CLINICAL STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 18, 2026 14:40 UTC
-
New drug combo targets Hard-to-Treat stomach cancers
Disease control OngoingThis study is testing whether adding an experimental drug called berzosertib to a standard chemotherapy drug (irinotecan) works better than the chemotherapy alone. It is for people with advanced stomach or esophageal junction cancer that has a specific genetic change (TP53 mutati…
Matched conditions: CLINICAL STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC
-
Hot chemo bath during surgery aims to stop stomach Cancer's return
Prevention ENROLLING_BY_INVITATIONThis study is testing a new approach to prevent stomach cancer from returning to the abdominal cavity after surgery. During the operation, doctors will wash the abdomen with a warm chemotherapy solution. The goal is to kill any stray cancer cells left behind to prevent the cancer…
Matched conditions: CLINICAL STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Prevention
Last updated Mar 27, 2026 12:39 UTC